NL8602140A - Werkwijze voor het verhinderen van een hypotensieve shock en gelokaliseerde botresorptie veroorzaakt door bacteriele endotoxinen. - Google Patents
Werkwijze voor het verhinderen van een hypotensieve shock en gelokaliseerde botresorptie veroorzaakt door bacteriele endotoxinen. Download PDFInfo
- Publication number
- NL8602140A NL8602140A NL8602140A NL8602140A NL8602140A NL 8602140 A NL8602140 A NL 8602140A NL 8602140 A NL8602140 A NL 8602140A NL 8602140 A NL8602140 A NL 8602140A NL 8602140 A NL8602140 A NL 8602140A
- Authority
- NL
- Netherlands
- Prior art keywords
- endotoxin
- peroxy
- diphosphate compound
- compound
- peroxy diphosphate
- Prior art date
Links
- 239000002158 endotoxin Substances 0.000 title claims description 63
- 238000000034 method Methods 0.000 title claims description 18
- 208000006386 Bone Resorption Diseases 0.000 title claims description 10
- 230000024279 bone resorption Effects 0.000 title claims description 10
- 208000001953 Hypotension Diseases 0.000 title claims description 6
- 208000021822 hypotensive Diseases 0.000 title claims description 6
- 230000001077 hypotensive effect Effects 0.000 title claims description 6
- 230000035939 shock Effects 0.000 title claims description 6
- -1 peroxy diphosphate compound Chemical class 0.000 claims description 27
- 239000001177 diphosphate Substances 0.000 claims description 21
- 235000011180 diphosphates Nutrition 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 231100000252 nontoxic Toxicity 0.000 claims description 7
- 230000003000 nontoxic effect Effects 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 125000001417 5'-guanylyl group Chemical group C=12N=C(N([H])[H])N([H])C(=O)C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 125000001572 5'-adenylyl group Chemical group C=12N=C([H])N=C(N([H])[H])C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000002510 pyrogen Substances 0.000 claims description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 2
- 229910052718 tin Inorganic materials 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 239000011135 tin Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 description 17
- 230000035605 chemotaxis Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 210000000988 bone and bone Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 7
- 241000700159 Rattus Species 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 4
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
- 102000013563 Acid Phosphatase Human genes 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 241000606750 Actinobacillus Species 0.000 description 1
- 208000002679 Alveolar Bone Loss Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- ULBTUVJTXULMLP-UHFFFAOYSA-N butyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCC ULBTUVJTXULMLP-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000007893 endotoxin activity Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- OKISBDHRUPZLOC-UHFFFAOYSA-N gallin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C(O)=C2OC2=C(O)C(O)=CC=C21 OKISBDHRUPZLOC-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000011268 leukocyte chemotaxis Effects 0.000 description 1
- 238000012454 limulus amebocyte lysate test Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002895 organic esters Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000004971 peroxyphosphoric acids Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76839685A | 1985-08-22 | 1985-08-22 | |
| US76839685 | 1985-08-22 | ||
| US85191586A | 1986-04-14 | 1986-04-14 | |
| US85191586 | 1986-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8602140A true NL8602140A (nl) | 1987-03-16 |
Family
ID=27118049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8602140A NL8602140A (nl) | 1985-08-22 | 1986-08-22 | Werkwijze voor het verhinderen van een hypotensieve shock en gelokaliseerde botresorptie veroorzaakt door bacteriele endotoxinen. |
Country Status (12)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2586350B1 (fr) * | 1985-08-22 | 1992-05-15 | Colgate Palmolive Co | Composition pharmaceutique a base de peroxodiphosphate pour l'inhibition de la secretion d'hormone parathyroidienne |
| DE4201858A1 (de) * | 1992-01-24 | 1993-07-29 | Renschler Aloys Dr Med | Mittel zur behandlung maligner zellen |
| NO20024880L (no) * | 2002-03-19 | 2003-09-22 | Per Hamre | Sammensetning inneholdende fosfat |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4041149A (en) * | 1976-01-12 | 1977-08-09 | Colgate-Palmolive Company | Composition and method of controlling and preventing mouth odor |
| US4430325A (en) * | 1981-12-23 | 1984-02-07 | Colgate-Palmolive Company | Topical treatment of skin lesions |
| DK168191B1 (da) * | 1984-06-27 | 1994-02-28 | Colgate Palmolive Co | Anvendelse af peroxydiphosphater til fremstilling af farmaceutiske tabletter eller farmaceutiske vandige opløsninger |
| US4975423A (en) * | 1984-06-27 | 1990-12-04 | Colgate-Palmolive Company | Inhibition of tumor development |
-
1986
- 1986-08-16 DE DE19863627759 patent/DE3627759A1/de not_active Ceased
- 1986-08-18 FR FR868611812A patent/FR2586351B1/fr not_active Expired - Lifetime
- 1986-08-19 IT IT48389/86A patent/IT1196587B/it active
- 1986-08-19 SE SE8603486A patent/SE468626B/sv not_active IP Right Cessation
- 1986-08-21 CA CA000516466A patent/CA1282004C/en not_active Expired - Lifetime
- 1986-08-22 CH CH3377/86A patent/CH670046A5/de not_active IP Right Cessation
- 1986-08-22 NL NL8602140A patent/NL8602140A/nl not_active Application Discontinuation
- 1986-08-22 GB GB8620482A patent/GB2180451B/en not_active Expired
- 1986-08-22 BE BE0/217073A patent/BE905319A/fr not_active IP Right Cessation
- 1986-08-22 DK DK402086A patent/DK168513B1/da not_active IP Right Cessation
-
1992
- 1992-10-14 SG SG1088/92A patent/SG108892G/en unknown
-
1993
- 1993-01-07 HK HK5/93A patent/HK593A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IT8648389A0 (it) | 1986-08-19 |
| DE3627759A1 (de) | 1987-03-19 |
| CA1282004C (en) | 1991-03-26 |
| DK168513B1 (da) | 1994-04-11 |
| BE905319A (fr) | 1987-02-23 |
| DK402086A (da) | 1987-02-23 |
| SE8603486L (sv) | 1987-02-23 |
| SG108892G (en) | 1992-12-24 |
| GB8620482D0 (en) | 1986-10-01 |
| SE8603486D0 (sv) | 1986-08-19 |
| DK402086D0 (da) | 1986-08-22 |
| GB2180451B (en) | 1989-10-18 |
| FR2586351A1 (fr) | 1987-02-27 |
| CH670046A5 (enrdf_load_html_response) | 1989-05-12 |
| FR2586351B1 (fr) | 1991-10-18 |
| IT1196587B (it) | 1988-11-16 |
| SE468626B (sv) | 1993-02-22 |
| GB2180451A (en) | 1987-04-01 |
| HK593A (en) | 1993-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0139535B1 (en) | Compositions for combatting toxaemia | |
| EP0226332B1 (en) | Veterinary compositions | |
| JP4700808B2 (ja) | フルボ酸、および種々の状態の処置におけるその使用 | |
| US11925612B2 (en) | Bactericidal and virucidal pharmaceutical composition | |
| NL8602140A (nl) | Werkwijze voor het verhinderen van een hypotensieve shock en gelokaliseerde botresorptie veroorzaakt door bacteriele endotoxinen. | |
| KR0143410B1 (ko) | B형 비루스성 간염치료용 제약학적 조성물 | |
| US5034383A (en) | Inactivation of bacterial endotoxins using peroxy-diphosphate compoounds | |
| JP2002530326A (ja) | 感染症の治療のためのホスホノ蟻酸誘導体の使用 | |
| US4975423A (en) | Inhibition of tumor development | |
| DK168191B1 (da) | Anvendelse af peroxydiphosphater til fremstilling af farmaceutiske tabletter eller farmaceutiske vandige opløsninger | |
| JPS5946208A (ja) | 抗菌性組成物 | |
| RU2115415C1 (ru) | Твердая дозированная форма для перорального применения, обладающая противовирусной активностью (варианты) | |
| RU2095063C1 (ru) | Фармацевтическая композиция, обладающая антибактериальным действием | |
| JPS62123121A (ja) | 細菌内毒素の不活化方法 | |
| HU203666B (en) | Process for producing pharmaceutical compositions containing dipyridamol for improving antiviral activity of interferone-alpha | |
| CN1328464A (zh) | 膦酰基甲酸衍生物在治疗感染中的应用 | |
| CA1307740C (en) | Pharmaceutical preparation and method for inhibiting replication of htlv-iii (aids) virus | |
| US3772438A (en) | Antibiotic compositions containing coumermycin | |
| NL8403948A (nl) | Antibacteriele geneesmiddelsamenstelling. | |
| US5028439A (en) | Inhibition of parathyroid hormone secretion | |
| NL8602139A (nl) | Remming van parathyroide hormoonsecretie. | |
| US20200289412A1 (en) | Bioenhanced spirulina lozenge formulation | |
| JP2001518093A (ja) | 細胞壁の生合成を阻害するウンデカプレノール・キナーゼ阻害剤の使用 | |
| PL157486B1 (en) | Method of obtaining mycose prevention and parasite killing preparations and mycose preventing and parasite killing preparation in particular for fighting against varrose jacobsoni oud |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| BV | The patent application has lapsed |